

Product Information

4-Nitrophenyl phosphate disodium salt hexahydrate

Tablet (20 mg substrate per tablet)

N2765

Product Description

CAS Registry Number: 333338-18-4

Synonyms: pNPP, *p*-Nitrophenyl Phosphate, Phosphatase substrateMolecular Formula: C₆H₄NNa₂O₆P • 6 H₂O

Formula Weight: 371.14

4-Nitrophenyl Phosphate (pNPP) is the substrate of choice for use with alkaline phosphatase conjugates in Enzyme Linked Immunosorbant Assay (ELISA) procedures, due to its high sensitivity.^{1,2} ELISA applications that use pNPP may be read in timed assays or stopped with alkaline solutions for delayed readings.³ This substrate produces a soluble end product that is yellow in color and can be read spectrophotometrically at 405 nm. The pNPP reaction may be stopped with the addition of 3 M NaOH solution and read at 405 nm.

The N2765 tablets are supplied as 50 tablets (50TAB) or 100 tablets (100TAB) per box, individually foil wrapped for ease of use, storage, and safety. Several theses^{4,5} and dissertations⁶⁻¹² have cited use of N2765 in their research protocols.

Precautions and Disclaimer

For R&D use only. Not for drug, household, or other uses. Please consult the Safety Data Sheet for information regarding hazards and safe handling practices.

Storage/Stability

The tablets should be stored at -20 °C.

Preparation Instructions

Tablets should be warmed to room temperature before use. Solutions should be freshly prepared.

Dissolve 1 tablet in either Glycine Buffer or Diethanolamine Buffer to the desired concentration. (Typically a pNPP concentration of 1 mg/mL is used.)

Glycine Buffer

To prepare 0.1 M glycine buffer, pH 10.4, with 1 mM MgCl₂ and 1 mM ZnCl₂:

- Add 7.51 g of glycine, 203 mg of MgCl₂, and 136 mg of ZnCl₂ to ~980 mL of water. Mix.
- Adjust pH to 10.4 with 19 M NaOH.
- Bring the volume to 1 L with water.

Diethanolamine Buffer

To prepare 1 M diethanolamine buffer, pH 9.8, with 0.5 mM MgCl₂:

- Add 97 mL of diethanolamine and 100 mg of MgCl₂ to 800 mL of water.
- Adjust pH to 9.8 with 10 M HCl.
- Bring the volume to 1 L with water.

Procedure

General ELISA procedure with alkaline phosphatase conjugates

- Add 200 µL of substrate solution (typically 1 mg/mL) per well.
- Incubate the plate in the dark for 30 minutes at room temperature.
- The absorbance can be read at 405 nm on a multiwell plate reader.
- The reaction may be stopped by adding 50 µL of 3 M NaOH per 200 µL of reaction mixture.

Troubleshooting

If the background is too high:

1. Use a blocking step prior to the application of the primary antibody. Normal Serum (5% v/v) from the same species as the host of the second antibody generally produces the best results.
2. Additional blocking agents for an ELISA are:
 - 0.05% TWEEN® 20 in 50 mM TBS, pH 8.0.
 - 1% BSA containing 0.05% TWEEN® 20 in 50 mM TBS, pH 8.0.

- 3% nonfat-dried milk in 0.01 M TBS (Cat. No. P2194). **Do not use milk as a blocking agent when using avidin-biotin systems.**
3. Use 0.05% TWEEN® 20 in all washing and antibody diluent buffers.
 4. Run control wells without the primary antibody to check for non-specific reactivity of the secondary antibody/alkaline phosphatase conjugate.
 5. Adjust the titer of the primary antibody and/or the alkaline phosphatase conjugate to determine the optimal working dilutions.

If no color develops or color is too faint:

1. Adjust the concentration of the primary antibody.
2. Adjust the concentration of the secondary antibody/alkaline phosphatase conjugate.
3. Determine if the enzyme conjugate is active by mixing a small sample of substrate and conjugate together in a test tube.
4. Increase the substrate incubation time or temperature.
5. Adjust the concentration of the coating antigen.
6. Consider using an amplifying system such as avidin-biotin.

References

1. Voller, A. et al., *Bull. World Health Organ.*, **53(1)**, 55-65 (1976).
2. Engvall, E., *Methods Enzymol.*, **70(A)**, 419-439 (1980).
3. Voller, A., and Bidwell, D., "Enzyme-linked immunosorbent assay", in *Manual of Clinical Laboratory Immunology*, 3rd ed. (Rose, N.R. et al., eds.). American Society for Microbiology (Washington, D.C.), pp. 99-109 (1986).
4. Abadie, Alicia Reneé, "Quantifying Cellulase in High-Solids Environments". University of Kentucky, M.S. thesis, p. 43 (2008).
5. Medeiros, Nicole, "*In Vivo* Expression of the Bacterial Amyloid Curli". Temple University, M.S. thesis, p. 25 (2016).
6. Chang, Li-Wen, "Development of Molecular Diagnostic Tests for Inclusion Body Disease in Boid Snakes". University of Florida, Ph.D. dissertation, p. 58 (2012).
7. Czeakańska, Ewa Maria, "*In vitro* cell and culture models for osteoblasts and their progenitors". Cardiff University, Ph.D. dissertation, pp. 46, 48 (2014).

8. Ali, Sarah AlFarabi, "Novel Biomarkers in the Diagnosis and Pathogenesis of Immunobullous Disorders". King's College London, Ph.D. dissertation, p. 184 (2015).
9. Sordé, Laetitia, "Anti-inflammatory effects of intravenous immunoglobulin (IVIg): what are the mechanisms of action?" Universität Basel, Ph.D. dissertation, p. 53 (2016).
10. Bore, Joseph Akoi, "Sero-prevalence of Ebola and Lassa virus in the Republic of Guinea, Macenta prefecture". University of Kent, Ph.D. dissertation, p. 65 (2020).
11. Jones, Shelby-Sara Ann, "The role of Lymphoblastic leukemia 1 (Lyl1) in *Mycobacterium tuberculosis* (Mtb) infection". University of Cape Town, Ph.D. dissertation, pp. 31, 54, 80 (2020).
12. Miller, Amanda Lynn, "Regulation and Expression of Amyloid Curli in *Salmonella* Infection". Temple University, Ph.D. dissertation, p. 95 (2021).

Notice

We provide information and advice to our customers on application technologies and regulatory matters to the best of our knowledge and ability, but without obligation or liability. Existing laws and regulations are to be observed in all cases by our customers. This also applies in respect to any rights of third parties. Our information and advice do not relieve our customers of their own responsibility for checking the suitability of our products for the envisaged purpose.

The information in this document is subject to change without notice and should not be construed as a commitment by the manufacturing or selling entity, or an affiliate. We assume no responsibility for any errors that may appear in this document.

Technical Assistance

Visit the tech service page at SigmaAldrich.com/techservice.

Terms and Conditions of Sale

Warranty, use restrictions, and other conditions of sale may be found at SigmaAldrich.com/terms.

Contact Information

For the location of the office nearest you, go to SigmaAldrich.com/offices.

The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada.

MilliporeSigma, and Sigma-Aldrich are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources.

© 2013-2022 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

N2765pis Rev 09/22 RBG,CMH,MAM,GCY

**MILLIPORE
SIGMA**